Abstract Background The Global COVID Vaccine Safety (GCoVS) Project, established in
2021 under the multinational Global Vaccine Data Network™(GVDN®), facilitates …

Summary Background Licensed mRNA COVID-19 vaccines require booster doses to sustain
SARS-CoV-2-specific responses, creating the need for novel, broadly immunogenic …

With the approval of the first vaccines against respiratory syncytial virus (RSV) and a novel
RSV‐neutralizing antibody, 2023 has been perceived as a game‐changing year in …

The long-term association between mRNA-based coronavirus disease 2019 (COVID-19)
vaccination and the development of autoimmune connective tissue diseases (AI-CTDs) …

In recent years, mRNA vaccine has achieved increasing interest owing to its high potency,
safety, ease of production, and low-cost manufacturing. Currently approved mRNA vaccines …

Pharmacovigilance plays a central role in safeguarding public health by continuously
monitoring the safety of vaccines, being critical in a climate of vaccine hesitancy, where …

Myocarditis after the COVID-19 vaccine is one of the important adverse events following
immunization, observed mainly after mRNA-based vaccines. Importantly, post-vaccination …

The current COVID-19 mRNA vaccines were developed and applied for pandemic-emergent
conditions. These vaccines use a small piece of the virus's genetic material (mRNA) to …

Objective The rapid deployment of COVID-19 mRNA vaccines, specifically Pfizer
(BNT162b2) and Moderna (mRNA-1273), had raised concerns about rare cardiac side …

At times of pandemics, such as the severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) infection, the situation demands rapid development and production timelines of safe …